DB-1324

DB-1324 is a preclinical, next-generation antibody-drug conjugate (ADC) developed by Duality Biologics using its proprietary and clinically validated Duality Immune Toxin Antibody Conjugate (DITAC) platform. The drug is designed to target gastrointestinal cancers, leveraging a topoisomerase inhibitor-based payload. Its mechanism of action involves modulation of the epidermal growth factor receptor (EGFR/erbB1) and receptor tyrosine-protein kinase erbB-3 (HER3), both implicated in tumor growth and survival. DB-1324 aims to address high unmet medical need in GI cancers, which account for a significant proportion of global cancer incidence and mortality. The ADC is positioned as a potentially best-in-class therapy with opportunities for combination regimens within oncology portfolios[1][2][3][8].